Abstract: Objective To investigate the efficacy and influencing factors of regional arterial perfusion combined with oxaliplatin neoadjuvant chemotherapy before radical gastrectomy in patients with stage III gastric cancer. Methods A retrospective study was conducted on 118 patients with primary gastric cancer diagnosed at Lishui Central Hospital in Zhejiang Province between March 2019 and March 2020. Based on whether they received interventional therapy before radical surgery, the patients were divided into an intervention group (n= 72) and a non-intervention group (n= 46). The non-intervention group proceeded directly to radical gastrectomy, while the intervention group received regional arterial perfusion combined with oxaliplatin neoadjuvant chemotherapy for 3 cycles before radical surgery. The tumor markers, overall survival rate and progression-free survival rate after 60 months of follow-up were compared between the two groups. A COX regression model was constructed to analyze the prognostic risk factors for patients undergoing this preoperative regimen. Results Levels of carcinoembryonic antigen (CEA), carbohydrate antigen (CA)19-9 and CA72-4 were lower after treatment in both groups compared to before treatment, and these tumor maker levels were lower in the intervention group than in the non-intervention group (P ＜ 0.05). The overall survival rate and progression-free survival rate in the intervention group were higher than those in the non-intervention group (P ＜ 0.05). COX regression analysis showed that CEA, CA19-9 and CA72-4 were independent risk factors of progression-free survival in patients with gastric cancer receiving regional arterial perfusion combined with oxaliplatin neoadjuvant chemotherapy before radical surgery (P ＜ 0.05). Conclusion Administering regional arterial perfusion combined with oxaliplatin neoadjuvant chemotherapy before radical gastrectomy can improve therapeutic efficacy and overall survival rate, and reduce tumor marker levels in patients with gastric cancer.